adxs31-142 + pembrolizumab

ADXS31-142 + pembrolizumab is a combination investigational therapy evaluated for metastatic castration-resistant prostate cancer (mCRPC). **ADXS31-142** is an attenuated *Listeria monocytogenes*-based immunotherapy engineered to target the prostate-specific antigen (PSA), designed to stimulate a PSA-specific T cell immune response. **Pembrolizumab** is a monoclonal antibody acting as a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor, promoting antitumor immunity by blocking the PD-1 pathway. Preclinical and clinical results indicate that combining ADXS31-142 with pembrolizumab extends and intensifies antigen-specific T cell expansion, enhances overall immune stimulation, and can promote antigen spreading to other prostate cancer-associated antigens. The combination showed a favorable safety profile and evidence of improved overall survival in mCRPC compared to monotherapy and warrants further clinical investigation[1][2][3].

Brand names

ADXS31-142 + pembrolizumab

Other names

ADXS31-142 with pembrolizumabADXS-31-142 with pembrolizumabADXS 31-142 with pembrolizumabADXS31-142 plus pembrolizumabADXS-31-142 plus pembrolizumabADXS 31-142 plus pembrolizumab